Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

NCT00980395 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Mantle Cell Lymphoma
Indolent Lymphoma
SLL

Interventions

DRUG: rituximab
DRUG: bortezomib
DRUG: cladribine

Sponsor

University of Arizona

Collaborators

[object Object]